Home World News Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients... World News Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 843 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR New Class of Compounds Rewires Cancer Cells to Self-Destruct August 29, 2023 Câncer em minha comunidade: Trabalhando para expandir o acesso a estudos... September 22, 2022 Coronavirus and cancer – July updates July 7, 2020 Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... June 2, 2021 Load more HOT NEWS EMA Starts Review of Rucaparib Experimental Drug Prevents Doxorubicin from Harming the Heart Bjorn Saven: “By supporting early career researchers to do their jobs... Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —...
